Country for PR: United Kingdom
Contributor: PR Newswire Europe
Tuesday, January 07 2020 - 09:00
genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models
LYON, France, Jan. 7, 2020 /PRNewswire-AsiaNet/ --

- genOway acquires additional rights to develop all animal cell models using 
the CRISPR/Cas9 system

genOway, a public company and leader in developing genetically modified 
research models, today announced an important milestone in extending its 
strategic alliance with Merck, a leading science and technology company and 
leader in genome editing.

In December 2018, genOway acquired from Merck exclusive worldwide rights on its 
foundational CRISPR/Cas9 portfolio in the rodent field (all applications 
involving rodent cells or animals). Today, the two companies have further 
strengthened their collaboration by entering into an additional license 
providing genOway with non-exclusive rights to commercialize the development 
and use of all other animal cell models for its customers' internal research 
uses as well as commercial exploitation.

"We are delighted to extend our relationship with Merck. The Merck IP is 
growing and broadening. Merck is now recognized as a leading provider of 
foundational CRISPR IP. This additional license will enable genOway to serve 
our customers better, by offering them broad and versatile solutions and the 
necessary intellectual property rights to help accelerate their research," says 
Alexandre Fraichard, founder and Chief Operating Officer of genOway.

Both Merck and genOway have identified research fields where they can combine 
their respective technologies and expertise to develop and validate new 
CRISPR/Cas9-related products and solutions. Merck's patented CRISPR integration 
technology is a strong entry point through which innovation can be developed 
and launched. 

About genOway

genOway (Euronext Growth(R): ALGEN; ISIN: FR0004053510) is a biotechnology 
society that operates in 28 countries in Europe, Asia and North America, and 
more than 260 research institutes and 80 biopharmaceutical companies. genOway's 
development is based on a broad and exclusive technology platform, as well as 
on strong intellectual property rights, combining patents and licensing 
agreements. The company has signed many commercial contracts with the leaders 
of the pharmaceutical industry (BMS, Janssen, Novartis, Pfizer, etc.), and with 
the most prestigious academic research centers, including the King's College 
and the University of Manchester in England; Harvard, Caltech and the National 
Institutes of Health in the United States; the Pasteur Institute in France; the 
German National Genome Research Network and the Max Planck Institute in Germany.

Logo - 

Sandrine Carteau 

SOURCE: genOway